MX344076B - Polipeptidos funcionalizados. - Google Patents

Polipeptidos funcionalizados.

Info

Publication number
MX344076B
MX344076B MX2012011299A MX2012011299A MX344076B MX 344076 B MX344076 B MX 344076B MX 2012011299 A MX2012011299 A MX 2012011299A MX 2012011299 A MX2012011299 A MX 2012011299A MX 344076 B MX344076 B MX 344076B
Authority
MX
Mexico
Prior art keywords
functionalized
polypeptides
functionalized polypeptides
improved
tissue
Prior art date
Application number
MX2012011299A
Other languages
English (en)
Inventor
Urech David
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of MX344076B publication Critical patent/MX344076B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a polipéptidos funcionalizados, especialmente polipéptidos terapéuticos (por ejemplo, scFv), que comprenden una secuencia enlazadora que puede funcionalizarse rápida y específicamente mediante la adición de una o de porciones funcionales (por ejemplo, PEG) o especificidades de unión (por ejemplo, una secuencia de aminoácidos con una especificidad de unión particular) Tales polipéptidos funcionalizados son ventajosos porque tienen propiedades farmacocinéticas mejoradas (por ejemplo, vida media in vivo mejorada, penetración de tejido y tiempo de residencia de tejido) sobre polipéptidos no funcionalizados. También se proporcionan métodos para la generación rápida y reproducible de polipéptidos funcionalizados.
MX2012011299A 2008-06-30 2009-06-30 Polipeptidos funcionalizados. MX344076B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7677508P 2008-06-30 2008-06-30
PCT/CH2009/000225 WO2010006454A2 (en) 2008-06-30 2009-06-30 Functionalized polypeptides

Publications (1)

Publication Number Publication Date
MX344076B true MX344076B (es) 2016-12-05

Family

ID=41139486

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012011299A MX344076B (es) 2008-06-30 2009-06-30 Polipeptidos funcionalizados.
MX2011000006A MX2011000006A (es) 2008-06-30 2009-06-30 Polipeptidos funcionalizados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000006A MX2011000006A (es) 2008-06-30 2009-06-30 Polipeptidos funcionalizados.

Country Status (12)

Country Link
US (3) US8637022B2 (es)
EP (2) EP2304033B1 (es)
JP (3) JP5988580B2 (es)
KR (2) KR101678925B1 (es)
CN (2) CN102089431A (es)
AU (1) AU2009270405B2 (es)
BR (1) BRPI0915343A2 (es)
CA (1) CA2729185A1 (es)
MX (2) MX344076B (es)
RU (2) RU2582244C2 (es)
WO (1) WO2010006454A2 (es)
ZA (1) ZA201008596B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110031373A (ko) 2008-07-10 2011-03-25 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 마크로분자 전달을 증강하는 방법 및 조성물
US20100056766A1 (en) * 2008-08-27 2010-03-04 Abbott Laboratories Purification of biological conjugates by size exclusion chromatography
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
CN109608543A (zh) 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
EP3122777B1 (en) 2014-03-26 2020-12-23 Cell Medica Switzerland AG Binding members to tnf alpha
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
KR20220062494A (ko) * 2019-08-15 2022-05-17 얀센 바이오테크 인코포레이티드 개선된 단일 사슬 가변 단편을 위한 재료 및 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9225453D0 (en) * 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US20050159343A1 (en) * 1999-03-26 2005-07-21 Board Of Regents, University Of Texas System Inhibitors of glycosaminoglycans
DK1165112T3 (da) 1999-03-26 2006-10-09 Univ Texas Modulatorer af polysaccharider og anvendelser deraf
AU7346400A (en) 1999-09-03 2001-04-10 School Of Pharmacy, University Of London, The Degradable polymers
EP1222217B1 (en) 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2406593A1 (en) * 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
US7211395B2 (en) * 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
CA2444098C (en) * 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
GB0131112D0 (en) 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
DK1506236T3 (da) * 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
AU2003301122B2 (en) 2002-12-19 2009-11-26 Nektar Therapeutics Cyanovirin variant-polymer conjugates
US7834258B2 (en) * 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
EP1769000B1 (en) * 2004-07-16 2014-12-24 Amgen Research (Munich) GmbH Expression-enhanced polypeptides
NZ553500A (en) * 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
CA2580796C (en) * 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US20060147862A1 (en) * 2005-01-06 2006-07-06 Jeffrey Bell Reduced smoking wick and candle
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
KR101457223B1 (ko) 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
RU2438708C2 (ru) 2006-07-10 2012-01-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк ScFv-АНТИТЕЛА, КОТОРЫЕ ПРОХОДЯТ ЧЕРЕЗ ЭПИТЕЛИАЛЬНЫЙ И/ИЛИ ЭНДОТЕЛИАЛЬНЫЙ СЛОИ
RU2010102064A (ru) 2007-06-25 2011-07-27 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
MX2009013328A (es) * 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
EP3216803B1 (en) * 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf

Also Published As

Publication number Publication date
WO2010006454A2 (en) 2010-01-21
WO2010006454A3 (en) 2010-03-25
ZA201008596B (en) 2012-02-29
AU2009270405A1 (en) 2010-01-21
CN102089431A (zh) 2011-06-08
US8637022B2 (en) 2014-01-28
US9371525B2 (en) 2016-06-21
JP2016147909A (ja) 2016-08-18
BRPI0915343A2 (pt) 2015-10-27
RU2016108598A (ru) 2018-11-23
JP5988580B2 (ja) 2016-09-07
MX2011000006A (es) 2011-08-03
EP3130603A1 (en) 2017-02-15
RU2011103168A (ru) 2012-08-10
JP2011526145A (ja) 2011-10-06
KR20160046927A (ko) 2016-04-29
EP2304033B1 (en) 2016-09-07
CA2729185A1 (en) 2010-01-21
KR101678925B1 (ko) 2016-11-24
KR101711472B1 (ko) 2017-03-02
US20160354479A1 (en) 2016-12-08
CN105153300A (zh) 2015-12-16
EP2304033A2 (en) 2011-04-06
RU2582244C2 (ru) 2016-04-20
AU2009270405B2 (en) 2014-06-05
JP2014111670A (ja) 2014-06-19
US20110200594A1 (en) 2011-08-18
KR20110039274A (ko) 2011-04-15
US20140178386A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX344076B (es) Polipeptidos funcionalizados.
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
CY1119183T1 (el) Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
PH12016500081B1 (en) Immunoglobulin variants and uses thereof
WO2008073458A3 (en) Fibrin-binding peptides and conjugates thereof
EA201391400A1 (ru) Способ производства конъюгатов с улучшенной гомогенностью
WO2011020783A3 (en) Targeted immunoconjugates
WO2010045598A3 (en) Psma binding ligand-linker conjugates and methods for using
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
WO2012088461A3 (en) Linker peptides and polypeptides comprising same
EP3838298A3 (en) Psma binding ligand-linker conjugates and methods for using
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
WO2011039510A3 (en) Conjugates targeting the cd163 receptor
TW200716179A (en) Transglutaminase mediated conjugation of growth hormone
WO2012166653A3 (en) Methods for coupling targeting peptides onto recombinant lysosomal enzymes
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2012135522A3 (en) Process for manufacturing conjugates of improved homogeneity
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
WO2010065954A3 (en) Sparc binding peptides and uses thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2008045976A3 (en) Compositions and methods for treating and diagnosing cancers
WO2008034120A3 (en) Lysine-based polymeric linkers
WO2009120893A3 (en) Polypeptide-polymer conjugates and methods of use thereof
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.